217
Participants
Start Date
March 31, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
March 31, 2016
Sarilumab
Pharmaceutical form: Solution Route of administration: Subcutaneous
Auto-Injector Device (AID)
Pre-filled Syringe (PFS)
Methotrexate
Dispensed according to local practice.
Sulfasalazine
Dispensed according to local practice.
Leflunomide
Dispensed according to local practice.
Hydroxychloroquine
Dispensed according to local practice.
Investigational Site Number 710001, Johannesburg
Investigational Site Number 710003, Durban
Investigational Site Number 710051, Port Elizabeth
Investigational Site Number 710011, Cape Town
Investigational Site Number 710007, Cape Town
Investigational Site Number 710050, Bellville
Investigational Site Number 840039, Albany
Investigational Site Number 840009, Duncansville
Investigational Site Number 840062, Reading
Investigational Site Number 840202, Hagerstown
Investigational Site Number 840016, North Charleston
Investigational Site Number 840236, Orlando
Investigational Site Number 840220, South Miami
Investigational Site Number 840229, Miami
Investigational Site Number 840155, Palm Harbor
Investigational Site Number 840152, Huntsville
Investigational Site Number 840025, Jackson
Investigational Site Number 840037, Tupelo
Investigational Site Number 484002, Guadalajara
Investigational Site Number 840224, Cincinnati
Investigational Site Number 840232, Flint
Investigational Site Number 840233, Kalamazoo
Investigational Site Number 484005, Monterrey
Investigational Site Number 840112, Lincoln
Investigational Site Number 840002, Oklahoma City
Investigational Site Number 840065, Tulsa
Investigational Site Number 840230, Carrollton
Investigational Site Number 840237, Plano
Investigational Site Number 840074, Mesquite
Investigational Site Number 840001, Dallas
Investigational Site Number 840020, Houston
Investigational Site Number 840239, Houston
Investigational Site Number 840241, Houston
Investigational Site Number 840242, Houston
Investigational Site Number 840038, Austin
Investigational Site Number 840069, Lubbock
Investigational Site Number 840223, Boulder
Investigational Site Number 840221, Peoria
Investigational Site Number 840226, Roseville
Investigational Site Number 484004, Mérida
Investigational Site Number 643020, Moscow
Investigational Site Number 643001, Moscow
Investigational Site Number 643008, Saint Petersburg
Investigational Site Number 643006, Kemerovo
Investigational Site Number 152007, Viña del Mar
Investigational Site Number 152005, Osorno
Investigational Site Number 152050, Santiago
Investigational Site Number 152014, Talca
Investigational Site Number 616002, Bialystok
Investigational Site Number 616005, Lublin
Investigational Site Number 616004, Warsaw
Investigational Site Number 616017, Warsaw
Investigational Site Number 616012, Wroclaw
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY